➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Colorcon
Moodys
McKinsey
Medtronic

Last Updated: May 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ALDARA

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Aldara

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00079300 Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer Completed National Naval Medical Center Phase 1 2004-01-01 RATIONALE: Biological therapies, such as imiquimod cream, work in different ways to stimulate the immune system and stop tumor cells from growing. PURPOSE: This randomized phase I trial is studying how well imiquimod cream works in treating patients with basal cell skin cancer.
NCT00176943 Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5% Completed National Alopecia Areata Foundation Phase 4 2000-10-01 It is thought that alopecia areata occurs as the result of an inappropriate response of the body's own immune system to certain substances in or around the hair follicle. We will be examining the efficacy of Aldara Cream 5% in treating extensive alopecia areata and observe its affect on the hair follicle.
NCT00176943 Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5% Completed Hordinsky, Maria K., MD Phase 4 2000-10-01 It is thought that alopecia areata occurs as the result of an inappropriate response of the body's own immune system to certain substances in or around the hair follicle. We will be examining the efficacy of Aldara Cream 5% in treating extensive alopecia areata and observe its affect on the hair follicle.
NCT00177021 Aldara for the Treatment of Extensive Alopecia Areata Completed 3M Phase 4 2000-10-01 We propose to examine the efficacy and tolerability of Aldara Cream 5% for the treatment of extensive alopecia areata. Aldara is a immune-response modifier. The drug induces the production of cytokines which are small, hormone-like proteins involved in cellular communication during immune responses. We hypothesize that this drug will effect the inflammatory cells present around hair follicles in patients with alopecia areata.
NCT00177021 Aldara for the Treatment of Extensive Alopecia Areata Completed National Alopecia Areata Foundation Phase 4 2000-10-01 We propose to examine the efficacy and tolerability of Aldara Cream 5% for the treatment of extensive alopecia areata. Aldara is a immune-response modifier. The drug induces the production of cytokines which are small, hormone-like proteins involved in cellular communication during immune responses. We hypothesize that this drug will effect the inflammatory cells present around hair follicles in patients with alopecia areata.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Aldara

Condition Name

Condition Name for Aldara
Intervention Trials
Actinic Keratosis 8
Actinic Keratoses 3
Metastatic Melanoma 2
Cutaneous Leishmaniasis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Aldara
Intervention Trials
Keratosis, Actinic 11
Keratosis 11
Carcinoma 5
Carcinoma, Basal Cell 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Aldara

Trials by Country

Trials by Country for Aldara
Location Trials
United States 91
Germany 8
France 4
Austria 4
Peru 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Aldara
Location Trials
Florida 9
Texas 6
Tennessee 5
California 5
Illinois 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Aldara

Clinical Trial Phase

Clinical Trial Phase for Aldara
Clinical Trial Phase Trials
Phase 4 8
Phase 3 11
Phase 2/Phase 3 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Aldara
Clinical Trial Phase Trials
Completed 23
Not yet recruiting 6
Recruiting 4
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Aldara

Sponsor Name

Sponsor Name for Aldara
Sponsor Trials
Graceway Pharmaceuticals, LLC 5
MEDA Pharma GmbH & Co. KG 4
3M 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Aldara
Sponsor Trials
Other 32
Industry 20
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
McKesson
McKinsey
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.